LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
Podcasts & Webcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
BioCentury-BayHelix China Healthcare Summit
East-West Healthcare Reception
BioCentury-BayHelix East-West Summit
Bio€quity Europe
Grand Rounds U.S.
Grand Rounds Europe
The BioCentury Show
Webinars - Upcoming & On-Demand
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Articles
Sierra Oncology Inc.
Headquarters:
San Mateo, CA, United States of America
Website:
N/A
Year Founded:
2004
Status:
Acquired
BioCentury
|
Nov 11, 2023
Data Byte
After a second look, EMA’s CHMP recommends Mirati’s KRAS inhibitor
CHMP’s November opinions include four new medicines and an expansion of Mounjaro’s label to include obesity
Read More
BioCentury
|
Oct 18, 2023
Data Byte
FDA’s NME approvals in September
Agency approved two new cancer and one new neuro drug; plus Amicus’ Pompe therapy among pair of approvals for rare metabolic disorders
Read More
BioCentury
|
Sep 15, 2023
Regulation
Sept. 15 Quick Takes: FDA approves GSK’s momelotinib, gained in $1.9B Sierra deal
Plus: Oral arguments in IRA suit consistent with briefs, and updates from Iovance and MAPS
Read More
BioCentury
|
Sep 6, 2023
Data Byte
11 PDUFA dates on FDA’s agenda in September
Decisions due this month include BioLineRx’s Aphexda, Roche’s subcutaneous Tecentriq and GSK’s momelotinib
Read More
BioCentury
|
Jun 16, 2023
Regulation
June 16 Quick Takes: Roche wins bispecific approval
Plus: FDA extends momelotinib’s review, and Neuvivo raises cash
Read More
BioCentury
|
Jun 1, 2023
Data Byte
At least 15 PDUFA dates on FDA’s calendar for June
Expected decisions include BioMarin’s hemophilia A gene therapy, a subQ form of argenx’s of myasthenia gravis drug, and Aldeyra’s retinal cancer candidate
Read More
BioCentury
|
Apr 19, 2023
Product Development
Gilead’s next steps in oncology
Ambitious top-10 goal in cancer by 2030, with BD focus on early-stage assets that add mechanisms to pipeline
Read More
BioCentury
|
Apr 18, 2023
Deals
Bellus’ focus on cough program pays off with $2B GSK buyout
Montreal biotech shed other programs, drove single asset through mid-stage trials to provoke takeout interest
Read More
BioCentury
|
Jan 9, 2023
Deals
CVRs address risks in billion-dollar AZ-CinCor, Ipsen-Albireo deals
Pair of high-premium M&A transactions could deliver shareholders more value tied to regulatory milestones
Read More
BioCentury
|
Oct 4, 2022
Management Tracks
Sause named CEO of Roche Diagnostics
Plus Kranzler becomes CEO of Urica, and updates from Pharus, Celularity, Cerevance and more
Read More
Items per page:
10
1 - 10 of 29